Title:
ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE
Document Type and Number:
WIPO Patent Application WO/2019/093435
Kind Code:
A1
Abstract:
A purpose of the present invention is to develop an immuno-viral therapy vector that has an optimal therapeutic effect while ensuring a high degree of safety, on the basis of the novel concept of finding the optimal expression level of a therapeutic gene to bring about the maximum therapeutic effect with no side effects. The present invention provides an oncolytic virus or similar that is characterized by having an immunogenic gene that is functionally linked downstream of an E2F promoter or a promoter demonstrating the same activity as an E2F promoter, wherein a promoter of nucleic acids coding for at least one factor that is essential for virus replication or assembly is substituted with a promoter of a factor for which expression is organ-specifically enhanced, or a promoter of a factor for which expression is cancer cell-specifically enhanced.
Inventors:
KOSAI KEN-ICHIRO (JP)
IJICHI NOBUHIRO (JP)
IJICHI NOBUHIRO (JP)
Application Number:
PCT/JP2018/041541
Publication Date:
May 16, 2019
Filing Date:
November 08, 2018
Export Citation:
Assignee:
UNIV KAGOSHIMA (JP)
International Classes:
C12N7/01; A61K35/761; A61K47/55; A61K48/00; A61P35/00; A61P35/04; A61P37/04; A61P43/00; C12N15/861
Domestic Patent References:
| WO2012043710A1 | 2012-04-05 | |||
| WO2005012536A1 | 2005-02-10 | |||
| WO2005030261A1 | 2005-04-07 | |||
| WO2005012536A1 | 2005-02-10 |
Foreign References:
| JP2013532977A | 2013-08-22 | |||
| JP2012525833A | 2012-10-25 | |||
| JP4478775B2 | 2010-06-09 | |||
| JP5963363B2 | 2016-08-03 | |||
| JP2005046101A | 2005-02-24 | |||
| JP2017215579A | 2017-12-07 | |||
| JP2018050722A | 2018-04-05 |
Other References:
ZHU MINGZHU ET AL.: "Linked Tumor-Selective Virus Replication and Transgene Expression from E3-Containing Oncolytic Adenoviruses", J. VIROL., vol. 79, no. 9, 2005, pages 5455 - 5465, XP055608896, ISSN: 0022-538X, DOI: 10.1128/JVI.79.9.5455-5465.2005
BRISTOL J. ANDREW ET AL.: "In Vitro and in Vivo Activities of an Oncolytic Adenoviral Vector Designed to Express GM-CSF", MOL. THER., vol. 7, no. 6, 2003, pages 755 - 764, XP009091891, DOI: 10.1016/S1525-0016(03)00103-5
KEN-ICHIRO KOSAI: "Development of conditionally replicating adenovirus with multiple factors (m-CRA) and theinvestigator-driven clinical trial : The original biotechnology moving toward the innovative medicineoriginating in Japan", EXPERIMENTAL MEDECINE, vol. 34, no. 1, 2006, pages 19 - 25, XP009520875, ISSN: 0288-5514
WATANABE KEISUKE ET AL.: "Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells", BLOOD, vol. 128, no. 22, 2016, pages 3360, XP002790340
YAN YANG ET AL.: "Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model", TUMOR BIOL., vol. 35, no. 2, Abstract, 14 September 2013 (2013-09-14) - February 2014 (2014-02-01), pages 1113 - 1122, XP055608905
BILSLAND, AE ET AL., F1000 RESEARCH., vol. 5, 2016, pages 2105
LIU BL ET AL., GENE THER., vol. 10, no. 4, 2003, pages 292 - 303
CHEN DS ET AL., IMMUNITY., vol. 39, no. 1, 2013, pages 1 - 10
CHEN SH ET AL., PROC NATL ACAD SCI U S A., vol. 92, no. 7, 1995, pages 2577 - 2581
KUMAGAI, T. ET AL., CANCER RES., vol. 56, no. 16, 1996, pages 3758 - 3762
CARUSO M ET AL., PROC NATL ACAD SCI U S A., vol. 93, no. 21, 1996, pages 11302 - 11306
NAGANO S ET AL., GENE THER., vol. 12, no. 18, 2005, pages 1385 - 1393
NEMUNAITIS J ET AL., MOL THER., vol. 18, 2010, pages 429 - 34
KAMIZONO J ET AL.: "Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication", CANCER RES., vol. 65, no. 12, 2005, pages 5284 - 5291, XP002997036, DOI: 10.1158/0008-5472.CAN-04-2657
TANOUE K ET AL., J TRANS MED., vol. 12, 2014, pages 27
TAKAKURA, M. ET AL., CANCER RES., vol. 59, 1999, pages 3143 - 3151
LI, F.ALTIERI, D.C., BIOCHEM. J., vol. 344, 1999, pages 305 - 311
TANAKA, M. ET AL., J. BIOL. CHEM., vol. 277, no. 12, 2002, pages 10719 - 26
KIMURA, M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 316, 2004, pages 930 - 6
MOL. CELL. BIOL., vol. 10, no. 6, 1990, pages 2738 - 2748
NEUMAN, E. ET AL., MOL. CELL. BIOL., vol. 14, no. 10, 1994, pages 6607 - 6615
MORRISON, N.A. ET AL., SCIENCE, vol. 246, 1989, pages 1158 - 1161
XIE, B. ET AL., BR. J. CANCER, vol. 81, 1999, pages 1335 - 1343
KOSHIKAWA, N. ET AL., CANCER RES., vol. 60, 2000, pages 2936 - 2941
GARVER, R.I. ET AL., GENE THER., vol. 1, 1994, pages 46 - 50
VILE, R.G. ET AL., CANCER RES., vol. 53, 1993, pages 962 - 967
PANDHA, H.S. ET AL., J. CLIN. ONCOL., vol. 17, 1999, pages 2180 - 2189
MOLECULAR THERAPY, vol. 18, 2010, pages 429 - 434
NAGANO ET AL., GENE THERAPY, vol. 12, 2005, pages 1385 - 1393
See also references of EP 3708657A4
BRISTOL J. ANDREW ET AL.: "In Vitro and in Vivo Activities of an Oncolytic Adenoviral Vector Designed to Express GM-CSF", MOL. THER., vol. 7, no. 6, 2003, pages 755 - 764, XP009091891, DOI: 10.1016/S1525-0016(03)00103-5
KEN-ICHIRO KOSAI: "Development of conditionally replicating adenovirus with multiple factors (m-CRA) and theinvestigator-driven clinical trial : The original biotechnology moving toward the innovative medicineoriginating in Japan", EXPERIMENTAL MEDECINE, vol. 34, no. 1, 2006, pages 19 - 25, XP009520875, ISSN: 0288-5514
WATANABE KEISUKE ET AL.: "Oncolytic Adenovirus Expressing Cytokines Enhances Anti-Tumor Efficacy of Mesothelin-Redirected CAR-T Cells", BLOOD, vol. 128, no. 22, 2016, pages 3360, XP002790340
YAN YANG ET AL.: "Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model", TUMOR BIOL., vol. 35, no. 2, Abstract, 14 September 2013 (2013-09-14) - February 2014 (2014-02-01), pages 1113 - 1122, XP055608905
BILSLAND, AE ET AL., F1000 RESEARCH., vol. 5, 2016, pages 2105
LIU BL ET AL., GENE THER., vol. 10, no. 4, 2003, pages 292 - 303
CHEN DS ET AL., IMMUNITY., vol. 39, no. 1, 2013, pages 1 - 10
CHEN SH ET AL., PROC NATL ACAD SCI U S A., vol. 92, no. 7, 1995, pages 2577 - 2581
KUMAGAI, T. ET AL., CANCER RES., vol. 56, no. 16, 1996, pages 3758 - 3762
CARUSO M ET AL., PROC NATL ACAD SCI U S A., vol. 93, no. 21, 1996, pages 11302 - 11306
NAGANO S ET AL., GENE THER., vol. 12, no. 18, 2005, pages 1385 - 1393
NEMUNAITIS J ET AL., MOL THER., vol. 18, 2010, pages 429 - 34
KAMIZONO J ET AL.: "Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication", CANCER RES., vol. 65, no. 12, 2005, pages 5284 - 5291, XP002997036, DOI: 10.1158/0008-5472.CAN-04-2657
TANOUE K ET AL., J TRANS MED., vol. 12, 2014, pages 27
TAKAKURA, M. ET AL., CANCER RES., vol. 59, 1999, pages 3143 - 3151
LI, F.ALTIERI, D.C., BIOCHEM. J., vol. 344, 1999, pages 305 - 311
TANAKA, M. ET AL., J. BIOL. CHEM., vol. 277, no. 12, 2002, pages 10719 - 26
KIMURA, M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 316, 2004, pages 930 - 6
MOL. CELL. BIOL., vol. 10, no. 6, 1990, pages 2738 - 2748
NEUMAN, E. ET AL., MOL. CELL. BIOL., vol. 14, no. 10, 1994, pages 6607 - 6615
MORRISON, N.A. ET AL., SCIENCE, vol. 246, 1989, pages 1158 - 1161
XIE, B. ET AL., BR. J. CANCER, vol. 81, 1999, pages 1335 - 1343
KOSHIKAWA, N. ET AL., CANCER RES., vol. 60, 2000, pages 2936 - 2941
GARVER, R.I. ET AL., GENE THER., vol. 1, 1994, pages 46 - 50
VILE, R.G. ET AL., CANCER RES., vol. 53, 1993, pages 962 - 967
PANDHA, H.S. ET AL., J. CLIN. ONCOL., vol. 17, 1999, pages 2180 - 2189
MOLECULAR THERAPY, vol. 18, 2010, pages 429 - 434
NAGANO ET AL., GENE THERAPY, vol. 12, 2005, pages 1385 - 1393
See also references of EP 3708657A4
Attorney, Agent or Firm:
NAKATANI Tomoko (JP)
Download PDF:
Previous Patent: ACETAMINOPHEN PREPARATION, AND METHOD FOR PRODUCING SAME
Next Patent: HEAT EXCHANGER
Next Patent: HEAT EXCHANGER